Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changesPathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.
Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.Peer-Reviewed Original ResearchBiochemical recurrenceAA raceCaucasian manProstate cancerAA menCaucasian raceEqual Access Regional Cancer Hospital (SEARCH) databaseClinical low-risk diseaseLow-risk prostate cancerRecurrence-free survival ratesCox proportional hazards analysisAdverse pathological findingsEqual-access health systemHigher median PSAImmediate radical prostatectomyLow-risk diseaseLow-risk tumorsPositive surgical marginsProportional hazards analysisLow-risk menAfrican American menUse of ASGleason upgradePathologic upgradingPathological upgrade